Author

Eimear Lagan

Edinburgh Cancer ResearchORCID 0000-0003-4176-8481Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

Adrian P. BrackeniD· 2 shared Craig MongeriD· 2 shared Gerard L. BrieniD· 2 shared Andrew A. MalcolmiD· 1 shared Andrew FlausiD· 1 shared Anthony M. DohertyiD· 1 shared April Chen· 1 shared Cheng WangiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adrian P. BrackenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJan 27, 2026

SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity

Anthony M. Doherty, Eimear Lagan, Richard J. R. Elliott…·Gerard L. Brien

This study shows SS18-SSX sustains oncogenic transcription without needing SWI/SNF activity, identifies P300 as a critical co-factor, and demonstrates targeting P300 or SWI/SNF as therapeutic strategies.

1 citation

humanDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 14, 2025

AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma

Daniel Angelov, James Nolan, Gráinne Holland…·Adrian P. Bracken

This study identifies AEBP2 as a therapeutic target in EZH2-mutant lymphoma by showing its role in maintaining H3K27me2 levels through a PRC2.2 complex.

DOI 10.1101/2025.10.14.682307

humanChIP-seq

𝕏 PostBluesky